Migraine-Specific Quality-of-Life Questionnaire (MSQ Version 2.1)

GlaxoSmithKline Research & Development Limited

Distributed by Mapi Research Trust

Distributed by Mapi Research Trust

default distrib

Basic description


GlaxoSmithKline Research & Development Limited

©1992, 1996, 1998 Glaxo Wellcome Inc
To assess quality of life related to migraine
Therapeutic area
  • Nervous System Diseases
Therapeutic indication

Migraine Disorders

Type of Clinical Outcome Assessment (COA)
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P. Validity and Reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.1). Headache 2000; 40:204-216 (PubMed abstract)

Jhingran P, Davis SM, LaVange LM, Miller DW, Helms RW. MSQ: Migraine-Specific Quality-of-Life Questionnaire. Further investigation of the factor structure. Pharmacoeconomics 1998; 13:707-17 (PubMed abstract)

Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache 1998; 38:295-302 (PubMed abstract)

Contact and conditions of use


GlaxoSmithKline Research & Development Limited

Contact information

Mapi Research Trust
27 rue de la Villette
69003 Lyon
Telephone: +33 (0)4 72 13 66 66

Conditions of use

Non-Commercial Users

If you do not receive specific funding for your study, you may download the questionnaire directly:

  1. Log in or Register for free
  2. Click the 'Online distribution' tab in the left menu bar and follow the instructions

Tutorials are available on our FAQs.

Commercial Users

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. In order to accelerate the process, you may attach the User Agreement (even if not finalized) to your online request. Click the link below for the user agreement template.
  4. Please do send the user agreement signed hard copy by regular mail to Mapi Research Trust
  5. Our PROVIDE team will get back to you with the needed information in a timely manner

Access fees

DISTRIBUTION FEES* Commercial users Cost per study 1 000 €
Cost per language 500 €
Funded academic research Cost per study Free
Cost per language Free
Not funded academic users Cost per study Free
Cost per language Free

It should be noted that the MSQ 2.1. is free from any royalty fee requested by the Owner, GlaxoSmithKline Research & Development Limited. 

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust.

Online distribution

For Non-Funded Academic Studies

The following licensing process is restricted to academic users:

  • Who do not receive specific funding for their study
  • Who intend to use the questionnaire in individual clinical practice or research study

Should you not correspond to this category of users, please send us a request.

Note: This site aims at providing you with the original version and existing translations of the questionnaire. However some modules/versions may not be downloadable in the language you need.

If you are interested in specific language(s), please first consult the list of existing translations in PROQOLID.


To access this section, please complete a client account.


Original language(s)

  • English for the USA


The list of translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study. This list is subject to constant changes, therefore please check the status of translations with Mapi Research Trust / the developers / copyright holders / distributors.

MSQ Version 2.1

Arabic for Israel*
Bulgarian for Bulgaria*
Czech for Czech Republic*
Danish for Denmark
Dutch for Belgium (Flemish)*
Dutch for the Netherlands*
English for Australia*
English for Canada
English for the UK
Finnish for Finland
French for Belgium*
French for Canada
French for France
French for Switzerland*
German for Austria*
German for Belgium*
German for Germany
German for Switzerland*
Hebrew for Israel*
Hungarian for Hungary*
Italian for Italy
Italian for Switzerland*
Japanese for Japan*
Polish for Poland*
Portuguese for Brazil*
Portuguese for Portugal*
Russian for Israel*
Russian for Russia*
Slovak for Slovakia*
Spanish for Mexico*
Spanish for Spain
Spanish for the USA*
Swedish for Finland*
Swedish for Sweden
Turkish for Turkey*
* Performed by Mapi

Conditions to translate

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.
Last update: February 2017
For additional information, please submit a request. More information in our FAQs.